Zobrazeno 1 - 10
of 519
pro vyhledávání: ''
Autor:
Yi Li, Guojun Yue, Hui Dong, Yunliang Cao, Fang Chen, Qiaoyuan Wu, Qing Luo, Yudi Dong, Ni Jiang
Publikováno v:
Anti-Cancer Drugs
Since the treatment of lung squamous cell carcinoma (SCC) was limited due to a lack of appropriate biomarkers and novel target agents. Immune checkpoint inhibitors can offer an effective treatment for patients with advanced non-small cell lung cancer
Publikováno v:
Anti-Cancer Drugs
OBJECTIVE A retrospective study was conducted to analyze which translational therapy, palliative chemotherapy and surgery is the best treatment for locally advanced and advanced pancreatic cancer, and to screen out the dominant population for the bes
Publikováno v:
Anti-Cancer Drugs. 33:e534-e540
We aimed to assess the prognostic and predictive significance of pretreatment Prognostic Nutritional Index (PNI) in extensive-stage small-cell lung cancer (ES-SCLC) patients treated with first-line chemotherapy. We designed this study to evaluate the
Publikováno v:
Anti-Cancer Drugs. 33:e584-e589
This retrospective study was conducted to explore the effects of anlotinib as first-line treatment for patients with advanced lung adenocarcinoma. We retrospectively reviewed medical records of 60 patients with advanced lung adenocarcinoma, admitted
Publikováno v:
Anti-Cancer Drugs. 33:e1-e8
Pyoderma gangrenosum is a rare ulcerative dermatosis. It may be caused by some drugs, including small molecule tyrosine kinase inhibitors (TKIs). The aim of this study was to evaluate the reported evidence of pyoderma gangrenosum associated with the
Publikováno v:
Anti-Cancer Drugs. 33:e491-e499
The most common pathological subtype of renal carcinoma is RCC, and its development is closely related to immune infiltration. In our study, we investigated the relationship between zinc finger protein 668 and the prognostic risk, clinical characteri
Publikováno v:
Anti-Cancer Drugs. 33:112-118
Brain metastasis is one of the common distant metastases of lung cancer. The prognosis of patients with brain metastasis is worse and the survival time is shorter. In this report, we described a rare mutation of EGFR G2607A (rs1050171) in two patient
Autor:
Tianwen Gao, Yanhong Zhao, Lei Wang, Tao Zhao, Weinan Guo, Guannan Zhu, Weigang Zhang, Qiong Shi, Lin Liu, Chunying Li, Yu Liu, Jianhong Zhao
Publikováno v:
Anti-Cancer Drugs. 32:1105-1110
Objectives Recombinant human interferon-α1b (IFN-α1b) is the first genetic engineered drug of China and is approved for cancer treatment by Chinese Food and Drug Administration. Although recombinant IFN-α1b is biologically and therapeutically acti
Publikováno v:
Anti-Cancer Drugs
The present study investigated the impact of major comorbidities, including hypertension, type 2 diabetes mellitus (T2DM), and chronic hepatitis B virus (HBV) infection, on the progression-free survival (PFS) and overall survival (OS) of extensive-st
Publikováno v:
Anti-Cancer Drugs. 32:882-885
Erlotinib is a tyrosine kinase inhibitor that inhibits epidermal growth factor receptor. It is being used for metastatic non-small cell lung cancer patients (NSCLC). Repurposing noncancer drugs for cancer treatment is a current issue and it has many